Broadcom named strategic vendor for Walmart virtualization solutions
On Friday, H.C. Wainwright analyst Ed Arce raised the price target on Mirum Pharmaceuticals (NASDAQ:MIRM) to $72 from the previous target of $66, while reiterating a Buy rating on the stock. According to InvestingPro data, the stock has experienced a -10.44% decline over the past week, though maintaining a remarkable 62.6% return over the last year. The revision follows Mirum’s recent announcement that it is on track to meet its 2025 global net product sales guidance, which forecasts an annual growth rate between 25% and 29%.
Mirum Pharmaceuticals, now with a market capitalization of $2.26 billion, reported that its LIVMARLI (maralixibat) net sales revenue for the fourth quarter of 2024 reached $64.1 million for the treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). This represents an 8.4% increase from the third quarter of 2024 and a significant 54.5% rise from the fourth quarter of 2023, contributing to the company’s impressive 80.76% revenue growth over the last twelve months. The company expects the sales for LIVMARLI’s PFIC indication to continue to grow steadily throughout 2025.
Additionally, Mirum is anticipating modest growth from its bile acid product portfolio, including Cholbam (cholic acid) and CTEXLI (chenodiol), especially after the FDA approved the marketing of these products for patients with cerebrotendinous xanthomatosis (CTX) on February 24, 2025. On the clinical development front, the Phase 3 EXPAND study of LIVMARLI commenced in the fourth quarter of 2024 and is progressing with the target to complete enrollment by 2026. Analysts maintain a strong bullish consensus on the stock, with price targets ranging from $54 to $74.
The company is also advancing its Phase 2 VISTAS study of volixibat, its second ileal bile acid transporter inhibitor (iBATi) program, for primary sclerosing cholangitis (PSC), with enrollment completion expected in the second half of 2025. The anticipated mid-2026 top-line data readout from this study is considered a critical milestone that could potentially support regulatory filings for volixibat in PSC treatment.
Arce highlighted Mirum’s position as a commercial-stage company that is expected to reach positive cash flow in 2025. With multiple clinical milestones on the horizon, the firm maintains a positive outlook on the company’s potential for additional upside.
In other recent news, Mirum Pharmaceuticals reported fourth-quarter earnings that did not meet analyst expectations, with an adjusted loss of $1.85 per share, significantly missing the forecasted loss of $0.30 per share. Despite this, the company achieved a revenue of $99.41 million, surpassing the consensus estimate of $95.4 million, marking a 55.6% increase year-over-year. For the full year 2024, Mirum’s total net product sales reached $336.4 million, a substantial increase from $178.9 million in 2023. The company’s LIVMARLI drug generated $213.3 million in sales for 2024, while its Bile Acid Medicines contributed $123.1 million. Mirum has provided guidance for 2025, projecting global net product sales between $420 million and $435 million, indicating continued growth. The company also anticipates achieving positive cash flow in 2025. Mirum ended 2024 with $292.8 million in cash, cash equivalents, and investments, an increase from $286.3 million at the end of 2023. Additionally, Mirum is looking forward to completing enrollment for its VISTAS study of volixibat in primary sclerosing cholangitis in the second half of 2025, with topline data expected in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.